FcγRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP)
- 7 October 2004
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 18 (12), 2038-2040
- https://doi.org/10.1038/sj.leu.2403536
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- FcγRIIB is differentially expressed during B cell maturation and in B‐cell lymphomasBritish Journal of Haematology, 2003
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)Blood, 2003
- In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomasBlood, 2003
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Molecular Basis of Fc Receptor FunctionAdvances in Immunology, 1994
- Soluble FCγ receptorsJournal of Leukocyte Biology, 1993